Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01873703 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
A Phase 2 study, sponsored by Helsinn Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 102
- Enrollment target
NCT01873703 is a Phase 2 study that has completed, run by Helsinn Healthcare. The registered enrollment target is 102 participants.
The verdict
NCT01873703, a Phase 2 study, has completed, sponsored by Helsinn Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 102 participants
- Enrollment target
Study Summary
The purpose of this randomized, double-blind, placebo-controlled study is to determine the safety and efficacy of pracinostat compared to placebo when combined with azacitidine, and FDA approved treatment for Myelodysplastic Syndrome (MDS).
Interventions
- DRUG Placebo
- DRUG Azacitidine
- DRUG pracinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01873703
The ClinicalTrials.gov registry entry for NCT01873703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Helsinn Healthcare, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01873703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01873703 about?
NCT01873703 is a clinical study titled "Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome". The purpose of this randomized, double-blind, placebo-controlled study is to determine the safety and efficacy of pracinostat compared to placebo when combined with azacitidine, and FDA approved treatment for Myelodysplastic Syndrome (MDS).
What is the current status of trial NCT01873703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 102 participants. The study started on 2013-06. Estimated completion is 2016-11.
What interventions are being tested in trial NCT01873703?
The interventions under investigation include: Placebo (DRUG), Azacitidine (DRUG), pracinostat (DRUG).
Who is sponsoring clinical trial NCT01873703?
This trial is sponsored by Helsinn Healthcare, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.